Genetically modified CD34+ cells exert a cytotoxic bystander effect on human endothelial and cancer cells - PubMed (original) (raw)
Affiliations
- PMID: 11106265
Genetically modified CD34+ cells exert a cytotoxic bystander effect on human endothelial and cancer cells
W O Arafat et al. Clin Cancer Res. 2000 Nov.
Abstract
We and others have proposed mammalian cells as gene delivery vehicles with the potential for overcoming physiological barriers to viral vectors. To that end, we previously have shown the potential of CD34+ endothelial progenitors for systemic gene delivery in a primate angiogenesis model. Here we seek to explore the utility of CD34+ cells of human origin as vehicles for toxin genes and, in particular, to measure their capacity to effect a cytotoxic bystander effect in human endothelium and tumor cells. To this end, CD34+ cells were transduced with TOZ.1, a nonreplicative herpes simplex vector encoding thymidine kinase. To test the capacity of CD34+ cells to induce a cytotoxic bystander effect in target cells, we performed mixing experiments, whereby TOZ.1-transduced CD34+ cells were mixed with either human vascular endothelial cells or human ovarian tumor cells (SKOV3.ip1). Cell viability was measured by the MTS assay. Lastly, mixtures of TOZ.1-transduced CD34+ cells and SKOV3.ip1 tumor cells were injected s.c. to evaluate the bystander effect in vivo. After transduction of CD34+ cells with TOZ.1, treatment with ganciclovir induced the killing of 99% of cells. In cell-mixing experiments, a linear correlation was observed between the percentages of TOZ.1-transduced CD34+ cells and total cell killing. For example, when 50% of CD34+ transduced cells were mixed with nontransduced SKOV3.ip1, >70% of all cells died. Similarly, when the same percentage was mixed with human vascular endothelial cells, >80% of the total number of cells died. In vivo studies showed an abrogation of tumor formation when TOZ.1-transduced CD34+ cells and ganciclovir were administered. Our observations establish the feasibility of a method for cell-based toxin gene delivery into disseminated areas of tumor angiogenesis.
Similar articles
- Endothelial cell vehicles for delivery of cytotoxic genes as a gene therapy approach for carcinoma of the ovary.
Rancourt C, Robertson MW 3rd, Wang M, Goldman CK, Kelly JF, Alvarez RD, Siegal GP, Curiel DT. Rancourt C, et al. Clin Cancer Res. 1998 Feb;4(2):265-70. Clin Cancer Res. 1998. PMID: 9516909 - Delivery of herpes simplex thymidine kinase bystander effect by engineered human mesothelial cells for the treatment of ovarian cancer.
Rancourt C, Bergeron C, Lane D, Garon G, Piché A. Rancourt C, et al. Cytotherapy. 2003;5(6):509-22. doi: 10.1080/14653240310003620. Cytotherapy. 2003. PMID: 14660047 - Purified herpes simplex virus thymidine kinase retroviral particles: III. Characterization of bystander killing mechanisms in transfected tumor cells.
Burrows FJ, Gore M, Smiley WR, Kanemitsu MY, Jolly DJ, Read SB, Nicholas T, Kruse CA. Burrows FJ, et al. Cancer Gene Ther. 2002 Jan;9(1):87-95. doi: 10.1038/sj.cgt.7700401. Cancer Gene Ther. 2002. PMID: 11916247 - Genetically modified CD34+ cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus model.
Gómez-Navarro J, Contreras JL, Arafat W, Jiang XL, Krisky D, Oligino T, Marconi P, Hubbard B, Glorioso JC, Curiel DT, Thomas JM. Gómez-Navarro J, et al. Gene Ther. 2000 Jan;7(1):43-52. doi: 10.1038/sj.gt.3301054. Gene Ther. 2000. PMID: 10680015 - [Implantation of genetically modified endothelial cells. A new promising technique for gene therapy].
Bi WL, Tang J. Bi WL, et al. Sheng Li Ke Xue Jin Zhan. 1992 Apr;23(2):162-3. Sheng Li Ke Xue Jin Zhan. 1992. PMID: 1411441 Review. Chinese. No abstract available.
Cited by
- Migratory neighbors and distant invaders: tumor-associated niche cells.
Wels J, Kaplan RN, Rafii S, Lyden D. Wels J, et al. Genes Dev. 2008 Mar 1;22(5):559-74. doi: 10.1101/gad.1636908. Genes Dev. 2008. PMID: 18316475 Free PMC article. Review. - Tumour vascularization: sprouting angiogenesis and beyond.
Hillen F, Griffioen AW. Hillen F, et al. Cancer Metastasis Rev. 2007 Dec;26(3-4):489-502. doi: 10.1007/s10555-007-9094-7. Cancer Metastasis Rev. 2007. PMID: 17717633 Free PMC article. Review. - AC133+ progenitor cells as gene delivery vehicle and cellular probe in subcutaneous tumor models: a preliminary study.
Rad AM, Iskander AS, Janic B, Knight RA, Arbab AS, Soltanian-Zadeh H. Rad AM, et al. BMC Biotechnol. 2009 Mar 27;9:28. doi: 10.1186/1472-6750-9-28. BMC Biotechnol. 2009. PMID: 19327159 Free PMC article. - Monitoring adenoviral based gene delivery in rat glioma by molecular imaging.
Varma NR, Barton KN, Janic B, Shankar A, Iskander A, Ali MM, Arbab AS. Varma NR, et al. World J Clin Oncol. 2013 Nov 10;4(4):91-101. doi: 10.5306/wjco.v4.i4.91. World J Clin Oncol. 2013. PMID: 24926429 Free PMC article. - Colony-stimulating factors for the management of neutropenia in cancer patients.
Dale DC. Dale DC. Drugs. 2002;62 Suppl 1:1-15. doi: 10.2165/00003495-200262001-00001. Drugs. 2002. PMID: 12479591 Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical